CA3141640A1 - Anti-gal9 immune-inhibiting binding molecules - Google Patents

Anti-gal9 immune-inhibiting binding molecules Download PDF

Info

Publication number
CA3141640A1
CA3141640A1 CA3141640A CA3141640A CA3141640A1 CA 3141640 A1 CA3141640 A1 CA 3141640A1 CA 3141640 A CA3141640 A CA 3141640A CA 3141640 A CA3141640 A CA 3141640A CA 3141640 A1 CA3141640 A1 CA 3141640A1
Authority
CA
Canada
Prior art keywords
gal9
antigen binding
binding molecule
cdrs
immune cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3141640A
Other languages
English (en)
French (fr)
Inventor
Michelle Wykes
Dileep K. Pulukkunat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of CA3141640A1 publication Critical patent/CA3141640A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3141640A 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules Pending CA3141640A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962855590P 2019-05-31 2019-05-31
US62/855,590 2019-05-31
US201962900105P 2019-09-13 2019-09-13
US62/900,105 2019-09-13
PCT/AU2020/050546 WO2020237320A1 (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Publications (1)

Publication Number Publication Date
CA3141640A1 true CA3141640A1 (en) 2020-12-03

Family

ID=73552467

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3141640A Pending CA3141640A1 (en) 2019-05-31 2020-05-29 Anti-gal9 immune-inhibiting binding molecules

Country Status (10)

Country Link
US (1) US20220227873A1 (https=)
EP (1) EP3976102A4 (https=)
JP (2) JP7797203B2 (https=)
KR (1) KR20220030934A (https=)
CN (1) CN114025797A (https=)
AU (1) AU2020285369A1 (https=)
CA (1) CA3141640A1 (https=)
IL (1) IL288561A (https=)
SG (1) SG11202113132YA (https=)
WO (1) WO2020237320A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220235135A1 (en) * 2019-05-31 2022-07-28 The Council Of The Queensland Institute Of Medical Research Activating anti-gal9 binding molecules
CR20240489A (es) * 2022-05-13 2025-01-07 Exelixis Inc Agentes aglutinantes 5t4 y usos de los mismos
PE20252168A1 (es) * 2023-01-27 2025-09-04 Exelixis Inc Agentes de union nkg2a y usos de estos
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511085A1 (en) * 1993-03-05 1994-09-15 Universite Catholique De Louvain Lo-cd2a antibody and uses thereof for inhibiting t-cell activation and proliferation
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003033709A2 (en) * 2001-10-17 2003-04-24 Bayer Healthcare Ag Regulation of human serine/threonine protein kinase
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
AR080795A1 (es) * 2010-03-24 2012-05-09 Genentech Inc Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
WO2016008005A1 (en) * 2014-07-14 2016-01-21 The Council Of The Queensland Institute Of Medical Research Galectin immunotherapy
CA3080120C (en) * 2017-10-27 2023-11-21 New York University Anti-galectin-9 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2025146842A (ja) 2025-10-03
JP2022534433A (ja) 2022-07-29
US20220227873A1 (en) 2022-07-21
EP3976102A4 (en) 2023-07-12
EP3976102A1 (en) 2022-04-06
WO2020237320A1 (en) 2020-12-03
CN114025797A (zh) 2022-02-08
SG11202113132YA (en) 2021-12-30
AU2020285369A1 (en) 2021-12-23
JP7797203B2 (ja) 2026-01-13
IL288561A (en) 2022-02-01
KR20220030934A (ko) 2022-03-11

Similar Documents

Publication Publication Date Title
US11891454B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
CN107614529B (zh) Pd-l1抗体、其抗原结合片段及其医药用途
JP7257971B2 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
JP7797203B2 (ja) 抗ｇａｌ９免疫阻害性結合分子
AU2019346598A1 (en) Anti- HLA-G antibodies, compositions comprising anti- HLA-G antibodies and methods of using anti- HLA-G antibodies
KR20210099027A (ko) 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
JP2025542239A (ja) 自己免疫疾患の治療
CN113637075A (zh) 双特异性抗原结合分子及其医药用途
US20220235135A1 (en) Activating anti-gal9 binding molecules
CA3164234A1 (en) Multi-specific antibodies
WO2021116277A1 (en) New antibody blocking human fcgriiia and fcgriiib
JP2025526279A (ja) 抗ＴＮＦα抗体および組成物
US20230374148A1 (en) Binding molecules that multimerise cd45
CN120882746A (zh) 结合至nkg2a和pd-l1的药剂及其用途
HK40088986A (zh) 多聚化cd45的结合分子
CN120051489A (zh) 抗cd100抗体及其用途
BR122024021001A2 (pt) Moléculas de ligação que multimerizam cd45, vetores, composição farmacêutica compreendendo as moléculas e uso

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240529

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250523

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250523

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251103

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260303

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260311

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260311